TIDMOKYO
OKYO Pharma Limited
27 April 2022
OKYO Pharma Limited
("OKYO", "OKYO Pharma" or the "Company")
OKYO Pharma Announces Two Presentations at the 2022 Association
for Research in Vision and Ophthalmology (ARVO) Annual Meeting
OK-101 ameliorates neuropathic corneal pain in a mouse model of
ciliary nerve ligation
BAM8-22 peptide analog OK-201 alleviates neuropathic corneal
pain in mice
London, April 27, 2022 - OKYO Pharma Limited (LSE: OKYO; OTCQB:
EMMLF), a biotechnology company focused on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and ocular pain, today announced that two presentations
will be given on OKYO drug candidates OK-101 and OK-201 at the
Association for Research and Vision in Ophthalmology (ARVO) Annual
Meeting, to be held on May 1-4, 2022 in Denver, CO and virtually on
May 11-12, 2022.
The oral presentation will highlight the ability of OK-101, a
novel agonist of the chemerin receptor ChemR23, to reduce
neuropathic corneal pain (NCP) in a mouse model of ciliary nerve
ligation; and the second presentation which will be given as a
poster, will present the efficacy data of OK-201, a BAM8-22 peptide
analog, in alleviating neuropathic corneal pain in the same mouse
model. These studies were conducted in collaboration with Pedram
Hamrah, MD, Interim Chair of Ophthalmology, cornea specialist, and
clinician-scientist at Tufts Medical Center, Boston, MA using a
mouse model of NCP developed in Dr. Hamrah's laboratory.
The presentation details are as follows:
Presentation Type: Paper Session
Presentation Number: 1834
Title: OK-101, A Novel Chemerin Receptor Agonist, Ameliorates
Neuropathic Corneal Pain in a Mouse Model of Ciliary Nerve
Ligation
Presenter: Harris, Deshea, Department of Ophthalmology, Tufts
Medical Center, Boston, MA
Presentation Date and Time: May 2, 2022, from 4:08 PM to 4:25 PM
MDT
Presentation Type: Poster Session
Posterboard Number: 1227 - A0227
Title: Proenkephalin-derived BAM8-22 peptide analogue alleviates
neuropathic corneal pain in mice
Presenter: Ayesha Sultan, Department of Ophthalmology, Tufts
Medical Center, Boston, MA
Poster Session Date/Times: May 2, 2022, from 10:00 AM to 12:00
PM MDT
About OKYO
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences
and biotechnology company admitted to listing on the standard
segment of the Official List of the UK Financial Conduct Authority
and to trading on the main market for listed securities of London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and ocular pain.
About Ocular Pain
Ocular pain is one of the most common causes for patient
referral to the emergency clinic, with substantial implications to
global quality of life and healthcare cost. Millions of people
suffer from ocular pain every year with no treatment approved by
the U.S. Food and Drug Administration for this condition. Side
effects and the risk of addiction to opioids is a serious concern.
Ocular pain may arise directly from tissue damage at the ocular
surface after surgery, injury, infection or from changes to
peripheral or central nerves in the ocular surface. Ocular
neuropathic pain refers to the increased perception of pain in
response to ordinarily non-painful stimuli and is often
misdiagnosed as dry eye disease. Current treatments are limited to
short term non-steroidal anti-inflammatory drugs, steroids, and
oral gabapentin and opioids in severe cases.
About OK-101
OK-101 is a novel long-acting G protein-coupled receptor-based
lipidated chemerin peptide developed to bind to ChemR23 receptors
typically found on immunological cells present in the eye. ChemR23
plays an important role in the inflammatory response, and binding
of OK-101 to ChemR23 has been shown to produce anti-inflammatory
activity in mouse models of dry-eye disease. OK-101 was developed
using a membrane-anchored-peptide (MAP) technology to produce a
long-acting drug candidate designed to combat washout through the
inclusion of a lipid 'anchor' within its molecular structure to
enhance residence time on the ocular surface.
About OK-201
MAS-Related G Protein-Coupled Receptors, or MRGPRs, mainly
expressed in the sensory neurons, are involved in the perception of
pain, thus making them a promising analgesic target. Activation of
MRGPR by Bovine Adrenal Medulla, or BAM, peptide inhibits pain
perception by modulating Ca2+ influx. OK-201, a BAM peptide
analogue, is a potent agonist of human MRGPR and a promising
candidate for the treatment of neuropathic and inflammatory
pain.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further information, please visit the Company's website at
www.okyopharma.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDSXUDDGDL
(END) Dow Jones Newswires
April 27, 2022 02:02 ET (06:02 GMT)
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024